We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

A Bacterial Lifestyle Switch Provides Antibiotic Resistance

By LabMedica International staff writers
Posted on 06 Jan 2016
Image: Light micrograph of Bacillus cereus in a small colony variant (SCV) (Photo courtesy of Markus Kranzler/Vetmeduni Vienna).
Image: Light micrograph of Bacillus cereus in a small colony variant (SCV) (Photo courtesy of Markus Kranzler/Vetmeduni Vienna).
Researchers have reported for the first time that following contact with certain antibiotics the pathogenic Bacillus cereus can switch into a special slowed-down mode and form small colony variants (SVCs) that are difficult to diagnose and almost impossible to treat with certain antibiotics.

Bacillus cereus causes vomiting and diarrhea as well as systemic and local infections such as sepsis or eye infections. The newly discovered mechanism, from a study led by researchers from the Vetmeduni Vienna (University of Veterinary Medicine Vienna (Austria), provides an explanation for this and possibly other cases of antibiotic resistance.

B. cereus had so far been considered to be exclusively endospore-forming in response to harsh conditions. The new study discovered an alternative lifestyle in which B. cereus forms SCVs in response to exposure to aminoglycoside antibiotics. The B. cereus SCVs grow slower, have an altered metabolism, and provide resistance to aminoglycosides. “The bacterium protects itself against the harmful effects of the antibiotics by forming these SCVs. But B. cereus is usually treated with exactly those antibiotics which induce the SCV state. If an antibiotic triggers the formation of SCVs, it also triggers resistance,” explained first author Dr. Frenzel.

The discovery of this mechanism is of great significance for clinical practice and will require rethinking diagnostics and therapy. Traditional diagnostics are based on identification of metabolic features of B. cereus, but these tests do not detect SCVs. This may result in incorrect antibiotic therapies or even failed diagnoses. Molecular tests may be the only way to diagnose this form of B. cereus. Treating B. cereus infections using only aminoglycoside antibiotics could bear the risk of a prolonged infection. SCVs grow more slowly, but they still produce toxins that are harmful to the body. “In this case, a combination therapy with other antibiotic groups is advisable,” Dr. Frenzel recommends.

Another bacterium, Staphylococcus aureus, also forms SCVs, but is capable of reverting to its original state. For B. cereus, the SCV form appears to be final, suggesting a new mechanism. “We believe that the SCV formation in B. cereus functions differently than in S. aureus,” said coauthor Dr. Ehling-Schulz.

“The ability to form SCVs appears to be of environmental significance for the bacteria,” said Dr. Frenzel, “B. cereus are soil-dwelling, and other microorganism in the soil produce antibiotics. Here, too, the formation of SCVs would be an advantage for the bacteria.”

The study, by Frenzel E, Kranzler M et al., was published December 8, 2015, in the journal mBio.

Related Links:

University of Veterinary Medicine Vienna


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Automated MALDI-TOF MS System
EXS 3000

Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The addition of Biocare’s complementary IHC antibody, reagent and instrument portfolio enhances Agilent’s immunohistochemistry offering (Photo courtesy of Biocare Medical)

Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical

Agilent Technologies (Santa Clara, CA, USA) has entered into a definitive agreement to acquire Biocare Medical (Pacheco, CA, USA), expanding its pathology portfolio through the addition of highly complementary... Read more
INTEGRA BIOSCIENCES AG